Trial Profile
A Real world, Retrospective Patient Review, Assessing Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jun 2018 New trial record